Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6

被引:20
作者
Gardiol, D [1 ]
Banks, L [1 ]
机构
[1] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy
关键词
D O I
10.1099/0022-1317-79-8-1963
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
An important characteristic of the E6 proteins derived from oncogenic associated human papillomaviruses (HPVs) is their ability to target the cellular tumour suppressor protein, p53, for ubiquitin mediated degradation. Several studies have attempted to address the important characteristics of both E6 and p53 for this activity in vitro, but the equivalent determinants have not been extensively assessed in vivo. Indeed, recent studies indicate differences between the in vitro and the in vivo degradation assays. We have performed an extensive analysis of the ability of a range of HPV-18 E6 mutants to direct p53 degradation in vivo. In addition, we have also compared the ability of HPV-18 E6 to direct the degradation of different oligomeric forms of p53 both in human and in murine cells. The results of these studies show that mutants of E6 exhibit very similar phenotypes both in vitro and in vivo. In contrast, mutants of p53 show markedly different susceptibilities in vitro and in vivo to EG-induced degradation, and this is further affected by the nature of the cell type in which the assays are performed. Finally, using a cell line temperature sensitive for the E1 ubiquitin-activating enzyme we have been able to show directly that this enzyme is involved in the process of EG-mediated degradation of p53 in vivo.
引用
收藏
页码:1963 / 1970
页数:8
相关论文
共 35 条
[1]   ENHANCED DEGRADATION OF P53 PROTEIN IN HPV-6 AND BPV-1 E6-IMMORTALIZED HUMAN MAMMARY EPITHELIAL-CELLS [J].
BAND, V ;
DALAL, S ;
DELMOLINO, L ;
ANDROPHY, EJ .
EMBO JOURNAL, 1993, 12 (05) :1847-1852
[2]   ISOLATION OF HUMAN-P53-SPECIFIC MONOCLONAL-ANTIBODIES AND THEIR USE IN THE STUDIES OF HUMAN P53 EXPRESSION [J].
BANKS, L ;
MATLASHEWSKI, G ;
CRAWFORD, L .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03) :529-534
[3]   PAPILLOMAVIRUS POLYPEPTIDE-E6 AND POLYPEPTIDE-E7 ARE ZINC-BINDING PROTEINS [J].
BARBOSA, MS ;
LOWY, DR ;
SCHILLER, JT .
JOURNAL OF VIROLOGY, 1989, 63 (03) :1404-1407
[4]   ACCUMULATION OF P53 IN A MUTANT-CELL LINE DEFECTIVE IN THE UBIQUITIN PATHWAY [J].
CHOWDARY, DR ;
DERMODY, JJ ;
JHA, KK ;
OZER, HL .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (03) :1997-2003
[5]   DEGRADATION OF P53 CAN BE TARGETED BY HPV E6 SEQUENCES DISTINCT FROM THOSE REQUIRED FOR P53 BINDING AND TRANSACTIVATION [J].
CROOK, T ;
TIDY, JA ;
VOUSDEN, KH .
CELL, 1991, 67 (03) :547-556
[6]   Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6 [J].
Crook, T ;
Ludwig, RL ;
Marston, NJ ;
Willkomm, D ;
Vousden, KH .
VIROLOGY, 1996, 217 (01) :285-292
[7]   Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells [J].
Dalal, S ;
Gao, QS ;
Androphy, EJ ;
Band, V .
JOURNAL OF VIROLOGY, 1996, 70 (02) :683-688
[8]   P53 FUNCTIONS AS A CELL-CYCLE CONTROL PROTEIN IN OSTEOSARCOMAS [J].
DILLER, L ;
KASSEL, J ;
NELSON, CE ;
GRYKA, MA ;
LITWAK, G ;
GEBHARDT, M ;
BRESSAC, B ;
OZTURK, M ;
BAKER, SJ ;
VOGELSTEIN, B ;
FRIEND, SH .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (11) :5772-5781
[9]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[10]   THE ABILITY OF HUMAN PAPILLOMAVIRUS E6 PROTEINS TO TARGET P53 FOR DEGRADATION IN-VIVO CORRELATES WITH THEIR ABILITY TO ABROGATE ACTINOMYCIN D-INDUCED GROWTH ARREST [J].
FOSTER, SA ;
DEMERS, GW ;
ETSCHEID, BG ;
GALLOWAY, DA .
JOURNAL OF VIROLOGY, 1994, 68 (09) :5698-5705